Curadev Pharma's Oncology Program With Endo Pharma Reaches Milestone

NEW DELHI, September 27, 2012 /PRNewswire/ --

Curadev Pharma Private Limited announced that it has successfully advanced its oncology program to the next stage with its clinical development partner, Endo Pharmaceuticals, USA, triggering a milestone payment.

Mr Manish Tandon, Chief Financial Officer at Curadev said, "Endo partnered with us when we had a good idea but no intellectual property. This collaboration is a validation of a new business paradigm in asset creation partnerships. We have had an excellent collaboration thus far and Curadev is committed to providing Endo with high quality assets. We are in the process of patenting three distinct series of molecules which are potent, bioavailable and show a pharmacodynamic effect in animals. There is a palpable sense of excitement that we could add a new weapon to the arsenal of oncologists." He added, "Curadev has quickly established a non-bureaucratic, decision-focused culture that respects individuals and this is critical for the success of an organization that depends on creativity."

Dr. Arjun Surya, Chief Scientific Officer at Curadev said, "This is an important milestone for our organization and it is very satisfying to see the progress of a program that has been conceived by our scientists. We have worked on a completely new program and have met and surpassed the efficacy and bioavailability criteria established jointly before starting the research program. A lot of credit must go to our core team whose cohesiveness, incisive thinking, work quality and speed have helped us meet our targets. This program is also a validation of our platform process that we use to find novel composition of matter since our each of our lead series have directly evolved from this process."

Dr. Sandeep Gupta, Senior Vice President, Discovery and Early Development at Endo stated, "We are extremely pleased with the creativity, productivity and collaborative spirit of the scientific team at Curadev. In a short span of less than one year, they have not only designed potent, novel molecules but also demonstrated activity of these molecules in animal models. I congratulate Curadev leadership and scientific team on achievement of this important milestone."  

About Curadev Pharma Pvt. Ltd.

Curadev Pharma is a New Delhi-based privately held small molecule discovery pharmaceutical company that focuses on the creation and licensing of pre-IND assets and IND packages for drug development. Curadev operates a collaborative, shared risk business model to partner with organizations that have the clinical development expertise. Curadev takes an 'out of the box' approach to identifying drug targets, drug design (using SAMORI, a proprietary hit finding process) and discovery research and has been able to quickly establish attractive research programs. The team's capabilities are supported by an accomplished international Scientific Advisory Board. For more information, visit www.curadev.in

Primary Media Contact: Manish Tandon, manish@curadev.in, 91-120-4081818